Immunitybio Operating Income from 2010 to 2025

IBRX Stock

USD 2.75 0.04 1.48%

Immunitybio Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Immunitybio generates from its operations. View All Fundamentals

Operating Income

First Reported

2015-06-30

Previous Quarter

-80.3 M

Current Value

-69.4 M

Quarterly Volatility

30.7 M

Yuan Drop

Covid

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 138.2 M or Selling General Administrative of 100.2 M, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or Days Sales Outstanding of 55.5. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.

Check out the analysis of Immunitybio Correlation against competitors.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Operating Income Growth Pattern

Below is the plot of the Operating Income of Immunitybio over the last few years. Operating Income is the amount of profit realized from Immunitybio operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Immunitybio is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Immunitybio's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Immunitybio Operating Income Regression Statistics

	Arithmetic Mean	(167,141,244)
	Geometric Mean	70,847,733
	Coefficient Of Variation	(85.32)
	Mean Deviation	125,381,399
	Median	(121,315,000)
	Standard Deviation	142,600,936
	Sample Variance	20335T
	Range	356M
	R-Value	(0.91)
	Mean Square Error	3775.2T
	R-Squared	0.83
	Slope	(27,233,842)
	Total Sum of Squares	305025.4T

Immunitybio Operating Income History

	2025	-327 M
	2024	-344.2 M
	2023	-362.2 M
	2022	-351.3 M
	2021	-330.3 M
	2020	-220.9 M
	2019	-156.3 M

Other Fundumenentals of Immunitybio

Non Operating Income Net Other

Immunitybio Operating Income component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Capital Stock	Net Working Capital	Deferred Long Term Liab	Short Long Term Debt
Total Assets		-0.44	-0.83	0.48	-0.74	0.63	0.23	0.74	0.95	0.42	0.61	0.67	-0.37	0.72	0.67	-0.68	0.57	0.09	-0.72	0.51	0.0	-0.22	0.56
Total Stockholder Equity	-0.44		0.32	-0.56	0.87	-0.63	0.02	-0.92	-0.27	-0.41	-0.67	-0.86	0.73	-0.86	-0.85	0.92	-0.72	0.2	0.89	-0.74	-0.01	0.5	-0.83
Current Deferred Revenue	-0.83	0.32		-0.34	0.7	-0.59	-0.44	-0.59	-0.69	-0.3	-0.59	-0.62	0.54	-0.6	-0.59	0.6	-0.37	0.04	0.54	-0.39	0.04	0.3	-0.45
Net Debt	0.48	-0.56	-0.34		-0.44	0.83	0.0	0.58	0.35	0.78	0.32	0.29	-0.29	0.64	0.37	-0.58	0.25	0.59	-0.52	0.03	-0.49	0.29	0.29
Retained Earnings	-0.74	0.87	0.7	-0.44		-0.68	-0.16	-0.97	-0.57	-0.36	-0.79	-0.98	0.76	-0.91	-0.93	0.96	-0.73	0.28	0.92	-0.81	-0.07	0.63	-0.86
Accounts Payable	0.63	-0.63	-0.59	0.83	-0.68		0.05	0.72	0.45	0.81	0.55	0.56	-0.49	0.78	0.64	-0.77	0.21	0.3	-0.68	0.23	-0.58	-0.09	0.53
Net Receivables	0.23	0.02	-0.44	0.0	-0.16	0.05		0.09	0.16	-0.05	0.01	0.11	-0.25	0.06	0.09	-0.06	0.12	-0.1	-0.05	0.09	0.08	-0.06	0.08
Total Liab	0.74	-0.92	-0.59	0.58	-0.97	0.72	0.09		0.59	0.46	0.76	0.94	-0.7	0.92	0.93	-0.97	0.77	-0.15	-0.96	0.76	0.03	-0.53	0.85
Total Current Assets	0.95	-0.27	-0.69	0.35	-0.57	0.45	0.16	0.59		0.32	0.42	0.53	-0.13	0.54	0.49	-0.49	0.5	0.17	-0.59	0.38	0.1	-0.16	0.35
Short Term Debt	0.42	-0.41	-0.3	0.78	-0.36	0.81	-0.05	0.46	0.32		0.33	0.22	-0.19	0.53	0.39	-0.48	-0.11	0.64	-0.55	-0.06	-0.82	0.1	0.28
Intangible Assets	0.61	-0.67	-0.59	0.32	-0.79	0.55	0.01	0.76	0.42	0.33		0.75	-0.78	0.67	0.83	-0.84	0.6	-0.37	-0.75	0.68	-0.1	-0.51	0.86
Common Stock	0.67	-0.86	-0.62	0.29	-0.98	0.56	0.11	0.94	0.53	0.22	0.75		-0.73	0.85	0.92	-0.92	0.75	-0.41	-0.89	0.85	0.2	-0.74	0.85
Short Term Investments	-0.37	0.73	0.54	-0.29	0.76	-0.49	-0.25	-0.7	-0.13	-0.19	-0.78	-0.73		-0.66	-0.75	0.79	-0.57	0.43	0.63	-0.64	-0.01	0.48	-0.77
Capital Surpluse	0.72	-0.86	-0.6	0.64	-0.91	0.78	0.06	0.92	0.54	0.53	0.67	0.85	-0.66		0.82	-0.93	0.63	-0.03	-0.88	0.72	-0.11	-0.32	0.82
Property Plant Equipment	0.67	-0.85	-0.59	0.37	-0.93	0.64	0.09	0.93	0.49	0.39	0.83	0.92	-0.75	0.82		-0.92	0.7	-0.33	-0.93	0.8	0.0	-0.67	0.9
Net Tangible Assets	-0.68	0.92	0.6	-0.58	0.96	-0.77	-0.06	-0.97	-0.49	-0.48	-0.84	-0.92	0.79	-0.93	-0.92		-0.71	0.21	0.92	-0.75	0.08	0.5	-0.89
Long Term Debt	0.57	-0.72	-0.37	0.25	-0.73	0.21	0.12	0.77	0.5	-0.11	0.6	0.75	-0.57	0.63	0.7	-0.71		-0.42	-0.68	0.83	0.57	-0.41	0.71
Net Invested Capital	0.09	0.2	0.04	0.59	0.28	0.3	-0.1	-0.15	0.17	0.64	-0.37	-0.41	0.43	-0.03	-0.33	0.21	-0.42		0.08	-0.62	-0.58	0.67	-0.47
Long Term Investments	-0.72	0.89	0.54	-0.52	0.92	-0.68	-0.05	-0.96	-0.59	-0.55	-0.75	-0.89	0.63	-0.88	-0.93	0.92	-0.68	0.08		-0.74	0.07	0.56	-0.83
Capital Stock	0.51	-0.74	-0.39	0.03	-0.81	0.23	0.09	0.76	0.38	-0.06	0.68	0.85	-0.64	0.72	0.8	-0.75	0.83	-0.62	-0.74		0.42	-0.63	0.9
Net Working Capital	0.0	-0.01	0.04	-0.49	-0.07	-0.58	0.08	0.03	0.1	-0.82	-0.1	0.2	-0.01	-0.11	0.0	0.08	0.57	-0.58	0.07	0.42		-0.29	0.02
Deferred Long Term Liab	-0.22	0.5	0.3	0.29	0.63	-0.09	-0.06	-0.53	-0.16	0.1	-0.51	-0.74	0.48	-0.32	-0.67	0.5	-0.41	0.67	0.56	-0.63	-0.29		-0.55
Short Long Term Debt	0.56	-0.83	-0.45	0.29	-0.86	0.53	0.08	0.85	0.35	0.28	0.86	0.85	-0.77	0.82	0.9	-0.89	0.71	-0.47	-0.83	0.9	0.02	-0.55

Click cells to compare fundamentals

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-344.2 M	-327 M
Non Operating Income Net Other	-2.2 M	-2.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunitybio Operating Income from 2010 to 2025

Latest Immunitybio's Operating Income Growth Pattern

Immunitybio Operating Income Regression Statistics

Immunitybio Operating Income History

Other Fundumenentals of Immunitybio

Immunitybio Operating Income component correlations

About Immunitybio Financial Statements

Also Currently Popular

Additional Tools for Immunitybio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY